Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy
- Conditions
- Ischemic Cardiomyopathy
- Interventions
- Biological: mesenchymal stem cells
- Registration Number
- NCT01946048
- Lead Sponsor
- Hebei Medical University
- Brief Summary
The aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .
- Detailed Description
Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all people with CAD are eligible for today's standard treatments. One new treatment approach uses umbilical cord blood derived mesenchymal stem cells-specialized cells capable of developing into other types of cells-to stimulate growth of new blood vessels for the heart. The aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
- Age from 30 to 80 years
- ischemic cardiomyopathy
- Left ventricular infarction area seriously low movement to no movement
- The low whole left ventricular systolic function (LVEF 45% or less)
- Have line or quasi coronary interventional treatment
- Willing to accept patients with follow-up evaluation
- Have signed informed consent form approved by the ethics committee
- Non elevation between S-wave and T-wave in patients with acute myocardial infarction
- No function damage in patients with acute myocardial infarction
- Acute myocardial infarction complicated with left ventricular aneurysm intends to do surgery
- Complications of acute myocardial infarction with other machines (including: ventricular septal perforation, papillary muscle rupture, etc.)
- Acute infectious diseases
- Blood system diseases, such as thrombocytopenia, severe anemia, leukemia, etc
- Severe renal disease, creatinine clearance < 36 ml/min, serum creatinine > 265 umol/L
- Laboratory tests suggest abnormal liver function, glutamate-pyruvate transaminase (ALT) > 4 times the upper limit of normal
- Unstable cerebral lesions
- malignant tumor
- Cognitive dysfunction and dementia patients, patients with severe mental illness
- Patients with severe physical disabilities can't regular follow-up
- Other serious uncontrolled system disease
- To prepare or have the pregnancy women patients
- Have a percutaneous coronary intervention contraindications: high-risk patients, such as the digestive tract, and intracranial hemorrhage or contrast allergy
- Cannot use the test dose atorvastatin
- Is not completed in accordance with the requirements for test the timing of the magnetic resonance imaging (MRI), PET, SPECT, follow-up testing (e.g., patients with implanted pacemakers or artificial joint)
- Patients unable or unwilling to sign a consent form
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description mesenchymal stem cells mesenchymal stem cells Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
- Primary Outcome Measures
Name Time Method The examination of heart function Post cell transplantation: 1, 3, 6 months Left ventricular ejection fraction： Change in left ventricular ejection fraction assessed with echocardiography after intramyocardial implantation of allogeneic mesenchymal stem cells.
- Secondary Outcome Measures
Name Time Method major adverse cardiac and cerebrovascular events Post cell transplantation: one year all-cause mortality Post cell transplantation: one year all-cause morbidity Post cell transplantation: one year
Trial Locations
- Locations (1)
the First Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China